Terlipressin in Hepatorenal Syndrome Type 1

Teuber, Peter

Abstract

Funding Agency

• Agency: National Institute of Health (NIH)
• Institute: Food and Drug Administration (FDA)
• Type: Research Project (R01)
• Project #: 5R01FD003024-02
• Application #: 7128120
• Study Section: Special Emphasis Panel (ZFD1-OPD (01))
• Program Officer: Ganti, Usha
• Project Start: 2005-09-15
• Project End: 2008-09-14
• Budget Start: 2006-09-15
• Budget End: 2007-09-14
• Support Year: 2
• Fiscal Year: 2006

Institution

• Name: Orphan Therapeutics, LLC
• City: Lebanon
• State: NJ
• Country: United States
• Zip Code: 08833

Publications

Boyer, Thomas D; Sanyal, Arun J; Garcia-Tsao, Guadalupe et al. (2011) Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol 55:315-21

Sanyal, Arun J; Boyer, Thomas; Garcia-Tsao, Guadalupe et al. (2008) A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology 134:1360-8